519 related articles for article (PubMed ID: 17100024)
1. Comparison of a restricted transfusion schedule with erythropoietin therapy versus a restricted transfusion schedule alone in very low birth weight premature infants.
Birenbaum HJ; Pane MA; Helou SM; Starr KP
South Med J; 2006 Oct; 99(10):1059-62. PubMed ID: 17100024
[TBL] [Abstract][Full Text] [Related]
2. [Usefulness of erythropoietin in the treatment of anemia of prematurity. Influence of birth weight].
Carbonell Estrany X; Figueras Aloy J; Pérez Fernández JM; Fernández López A; González Luis G; Salvía Roiges MD
An Esp Pediatr; 1999 Sep; 51(3):281-6. PubMed ID: 10575752
[TBL] [Abstract][Full Text] [Related]
3. Early erythropoietin influences both transfusion and ventilation need in very low birth weight infants.
Tempera A; Stival E; Piastra M; De Luca D; Ottaviano C; Tramontozzi P; Marconi M; Cafforio C; Marcozzi P; Rossi N; Buffone E
J Matern Fetal Neonatal Med; 2011 Aug; 24(8):1060-4. PubMed ID: 21250913
[TBL] [Abstract][Full Text] [Related]
4. Follow-up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity.
Soubasi V; Kremenopoulos G; Diamanti E; Tsantali C; Sarafidis K; Tsakiris D
J Pediatr; 1995 Aug; 127(2):291-7. PubMed ID: 7636658
[TBL] [Abstract][Full Text] [Related]
5. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group.
Maier RF; Obladen M; Scigalla P; Linderkamp O; Duc G; Hieronimi G; Halliday HL; Versmold HT; Moriette G; Jorch G
N Engl J Med; 1994 Apr; 330(17):1173-8. PubMed ID: 8139627
[TBL] [Abstract][Full Text] [Related]
6. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron.
Ohls RK; Ehrenkranz RA; Das A; Dusick AM; Yolton K; Romano E; Delaney-Black V; Papile LA; Simon NP; Steichen JJ; Lee KG;
Pediatrics; 2004 Nov; 114(5):1287-91. PubMed ID: 15520109
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin and prematurity--where do we stand?
Carbonell-Estrany X; Figueras-Aloy J; Alvarez E
J Perinat Med; 2005; 33(4):277-86. PubMed ID: 16207112
[TBL] [Abstract][Full Text] [Related]
8. Early treatment of premature infants with recombinant human erythropoietin.
Messer J; Haddad J; Donato L; Astruc D; Matis J
Pediatrics; 1993 Oct; 92(4):519-23. PubMed ID: 8414820
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human erythropoietin in the treatment of anemia of prematurity.
Chen JY; Wu TS; Chanlai SP
Am J Perinatol; 1995 Sep; 12(5):314-8. PubMed ID: 8540930
[TBL] [Abstract][Full Text] [Related]
10. In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study.
Soubasi V; Kremenopoulos G; Diamandi E; Tsantali C; Tsakiris D
Pediatr Res; 1993 Nov; 34(5):675-9. PubMed ID: 8284109
[TBL] [Abstract][Full Text] [Related]
11. [Does human recombinant erythropoetin /R-HU-EPO/ treatment for anemia of prematurity have any effect on reducing the number of blood transfusions?].
Pramatarova T; Jarukova N; Sluncheva B; Vakrilova L; Emilova Z; Nikolov A; Dimitrov A
Akush Ginekol (Sofiia); 2010; 49(2):13-9. PubMed ID: 20734672
[TBL] [Abstract][Full Text] [Related]
12. A randomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants.
Ohls RK; Christensen RD; Kamath-Rayne BD; Rosenberg A; Wiedmeier SE; Roohi M; Lacy CB; Lambert DK; Burnett JJ; Pruckler B; Schrader R; Lowe JR
Pediatrics; 2013 Jul; 132(1):e119-27. PubMed ID: 23776118
[TBL] [Abstract][Full Text] [Related]
13. [Prophylaxis of anemia of prematurity with erythropoietin. Case control study].
de la Torre Aguilar M; Gascón Jiménez FJ; Zapatero Martínez M; Guzmán Cabañas J; Huertas Muñoz D; Ruiz González D; Jaraba Caballero P
An Esp Pediatr; 2000 Sep; 53(3):243-8. PubMed ID: 11083968
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin and blood transfusion in low-birth weight preterm infants under restrictive transfusion guidelines.
Badiee Z; Pourmirzaiee MA; Kelishadi R; Naseri F
Saudi Med J; 2006 Jun; 27(6):817-20. PubMed ID: 16758042
[TBL] [Abstract][Full Text] [Related]
15. Current controversies in the management of the anemia of prematurity.
Bishara N; Ohls RK
Semin Perinatol; 2009 Feb; 33(1):29-34. PubMed ID: 19167579
[TBL] [Abstract][Full Text] [Related]
16. [Prevention of neonatal anemia with recombinant human erythropoietin: a cost-benefit analysis].
Schefels J; Merz U; Hörnchen H
Z Geburtshilfe Neonatol; 1999 Dec; 203 Suppl 2():1-5. PubMed ID: 10612190
[TBL] [Abstract][Full Text] [Related]
17. Growth, efficacy, and safety of feeding an iron-fortified human milk fortifier.
Berseth CL; Van Aerde JE; Gross S; Stolz SI; Harris CL; Hansen JW
Pediatrics; 2004 Dec; 114(6):e699-706. PubMed ID: 15545616
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.
Shannon KM; Keith JF; Mentzer WC; Ehrenkranz RA; Brown MS; Widness JA; Gleason CA; Bifano EM; Millard DD; Davis CB
Pediatrics; 1995 Jan; 95(1):1-8. PubMed ID: 7770284
[TBL] [Abstract][Full Text] [Related]
19. Financial impact of the introduction of erythropoietin in the treatment of anemia of premature infants in Israel.
Dollberg S; Mimouni FB
Isr Med Assoc J; 1999 Oct; 1(2):86-8. PubMed ID: 10731302
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of anaemia of prematurity with SS-R-Hu-erythropoietin and significance of hypoxia-inducible factor].
Pramatarova T; Sluncheva B; Jarukova N; Vakrilova L; Emilova Z; Shishkova R; Dimitrov A; Nikolov A; Radulova P; Chitrova S
Akush Ginekol (Sofiia); 2010; 49(1):11-7. PubMed ID: 20734660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
